Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES | O14684 | 5/20 | 0.58 |
| ▸ | NR1H4 | Q96RI1 | 4/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | APEX1 | P27695 | 1/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672227 | 0.87 | NR1H4 (0.48) | PTGESNR1H4EPHX2SMN1; SMN2RIPK1 | |
| SCHEMBL14965812 | 0.85 | PTGES (0.56) | PTGESNR1H4HDAC6CA1CA2 | |
| SCHEMBL17199216 | 0.84 | PTGES (0.59) | PTGESNR1H4HDAC6CA1CA2 | |
| SCHEMBL1671704 | 0.84 | PTGES (0.59) | PTGESNR1H4HDAC6CA1CA2 | |
| SCHEMBL30901987 | 0.82 | NR1H4 (0.50) | PTGESNR1H4CA1CA2EPHX2 | |
| SCHEMBL14979282 | 0.82 | NR1H4 (0.50) | PTGESNR1H4CA1CA2EPHX2 | |
| SCHEMBL25587378 | 0.81 | HDAC6 (0.53) | PTGESNR1H4HDAC6CA1CA2 | |
| SCHEMBL31169339 | 0.81 | PTGES (0.60) | PTGESNR1H4HDAC6CA1CA2 | |
| SCHEMBL1671417 | 0.81 | PTGES (0.60) | PTGESNR1H4HDAC6CA1CA2 | |
| SCHEMBL11978600 | 0.80 | HDAC6 (0.51) | PTGESNR1H4HDAC6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2655335-A1 | NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS | Eli Lilly and Company (US) | 2013-10-30 | — | — | EP | disclosed |
| US-8252831-B2 | Imidazole-2-benzamide compounds useful for the treatment of osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-08-28 | — | — | US | disclosed |
| WO-2012087771-A1 | NOVEL IMIDAZOLE-2-BENZAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF OSTEOARTHRITIS | ELI LILLY AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ELI LILLY AND COMPANY (US) | 2012-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120157506-A1 | Novel Imidazole-2-Benzamide Compounds Useful for the Treatment of Osteoarthritis | ARG2, HDAC6, COL2A1 | PTGES 550/4885NR1H4 1205/4885HDAC6 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.